Spots Global Cancer Trial Database for AZD9833 China PK Study
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: AZD9833 China PK Study
Official Title: A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination With Palbociclib or Everolimus in Chinese Patients With Oestrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer (mBC)
Study ID: NCT04818632
Conditions
Study Description
Brief Summary: A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination in Chinese patients with ER Positive, HER2 Negative, Metastatic Breast Cancer
Detailed Description: This study is designed to investigate and characterize the safety, tolerability and PK of AZD9833 monotherapy (Part A, Part B-cohort 1) or in combination with palbociclib (optional Part B cohort 2) or everolimus (optional Part B cohort 3) and to explore the preliminary anti-tumour activity in Chinese patients
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Research Site, Beijing, , China
Research Site, Chengdu, , China
Research Site, Shanghai, , China
Research Site, Wuhan, , China
Contact Details
Name: Jiong Wu
Affiliation: Department of Breast Surgery, Fudan University Shanghai Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Name: Jian Zhang
Affiliation: Department of Medical Oncology, Fudan University Shanghai Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
